| Project/Area Number |
26462029
|
|---|
| Research Category |
Grant-in-Aid for Scientific Research (C)
|
| Allocation Type | Multi-year Fund |
|---|
| Section | 一般 |
|---|
| Research Field |
Digestive surgery
|
|---|
| Research Institution | Toho University |
|---|
Principal Investigator |
|
|---|
| Co-Investigator(Kenkyū-buntansha) |
島田 英昭 東邦大学, 医学部, 教授 (20292691)
牛込 充則 東邦大学, 医学部, 助教 (90408849)
鈴木 孝之 東邦大学, 医学部, 助教 (10385768)
|
|---|
| Project Period (FY) |
2014-04-01 – 2019-03-31
|
| Project Status |
Completed (Fiscal Year 2018)
|
| Budget Amount *help |
¥4,940,000 (Direct Cost: ¥3,800,000、Indirect Cost: ¥1,140,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
Fiscal Year 2014: ¥1,040,000 (Direct Cost: ¥800,000、Indirect Cost: ¥240,000)
|
|---|
| Keywords | RalA / p53 / 大腸癌 / 血清抗体 / 腫瘍マーカー / SEREX / CEA |
|---|
| Outline of Final Research Achievements |
【Background and Purpose】Anti-RalA-IgG antibodies appear in the serum of cancer patients from the early stages of carcinogenesis. This serum RalA-IgG antibody is developed as a novel biomarker.【Patients and Methods】Preoperative serum and resected specimen were analyzed in 289 patients with colorectal cancer.【Results】 The positive rate of serum RalA-IgG antibody was 14%. The positive rate increased as the stage progression, but the relevance to the prognosis was unclear. Serum antibodies were not correlated with CEA, CA19-9 nor p53 antibodies. Immunostaining of tissues showed a moderate correlation with serum antibody titer.【Conclusion】Serum RalA antibody in the patients with colorectal cancer seems to be useful.
|
| Academic Significance and Societal Importance of the Research Achievements |
既存の腫瘍マーカーであるCEA, CA19-9, p53抗体いずれの陰性である約４０％の大腸癌症例で一定の陽性率となることから、CEA,CA19-9,p53抗体のいずれとも独立している血清RALA抗体検査の意義がある。血液検査による大腸癌のスクリーニングに寄与するものと思われる。
|
